Background Changes in federal policy during the COVID-19 pandemic allowing for the use
of telemedicine to treat opioid use disorder (OUD) have facilitated innovative strategies to …

Objectives: The purpose of this study was to assess the feasibility and clinical impact of
telemedicine-based opioid treatment with buprenorphine-naloxone following the …

Low barrier addiction clinics increase access to medications to treat substance use
disorders, while emphasizing harm reduction. The Harm Reduction and BRidges to Care …

Background: To reduce coronavirus disease 2019 (COVID-19) spread, federal agencies
eased telemedicine restrictions including audio-only appointments. These changes …

Introduction Opioid use disorder (OUD) is a debilitating illness that remains a serious public
health issue in the United States. Use of telemedicine to deliver m edications for the …

Background: To reduce the spread of coronavirus disease 2019 (COVID-19), many
substance use disorder treatment programs have transitioned to telemedicine. Emergency …

Background Telemedicine-delivered buprenorphine (tele-buprenorphine) can potentially
increase access to buprenorphine for patients with opioid use disorder (OUD), especially …

Background To determine how clinicians with a DATA waiver to prescribe buprenorphine for
opioid use disorder (OUD) adapted during the COVID-19 pandemic to emergency …

Despite its proven efficacy, buprenorphine remains dramatically underutilized for
management of opioid use disorder largely due to onerous barriers to treatment initiation …

Federal regulatory changes during the COVID-19 pandemic allow buprenorphine to be
prescribed without an initial in-person evaluation. Prior to COVID-19, numerous barriers …